1 |
Ulmer W, Pyyry J, Kaissi W: 3D photon superposition/ convolution algorithm and its foundation on results of Monte Carlo calculations, Phys Med Biol, 50(8), 1767-1790, 2005
DOI
|
2 |
Geh JI, Bond SJ, Bentzen SM, Glymme-Jones R: Systematic overview of preoperative (neoadjuvant) chemo-radiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response, Radiother Oncol, 78(3), 236-234, 2006
DOI
|
3 |
Webb S, Nahum AE: A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density, Phys Med Biol, 38(6), 653-666, 1993
DOI
|
4 |
Gagliardi G, Constine LS, Moiseenko V, et al: Radiation dose-volume effects in the heart, Int J Radiat Oncol Biol Phys, 76, S77-85, 2010
DOI
|
5 |
Lyman JT: Complication probability as assessed from dose-volume histograms, Radiat Res Suppl, 8, S13-19, 1985
DOI
|
6 |
Kutcher GJ, Burman C: Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method, Int J Radiat Oncol Biol Phys, 16(6), 1623-1630, 1989
DOI
|
7 |
Keall PJ, Mageras GS, Balter JM et al.: The management of respiratory motion in radiation oncology report of AAPM Task Group 76, Med Phys, 33(10), 3874-3900, 2006
DOI
|
8 |
Cohen RJ, Paskalev K, Litwin S, Price RA Jr, Feigenberg SJ, Konski AA: Esophageal motion during radiotherapy: quantification and margin implications, Dis Esophagus, 23(6), 473-479, 2010
DOI
|
9 |
Gao XS, Qiaol X, Cao L et al.: Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma, Int J Radiat Oncol Biol Phys, 67(2), 389-396, 2007
DOI
|
10 |
Welsh J, Palmer MB, Aiani JA et al.: Esophageal cancer dose escalation using a simultaneous integrated boost technique, Int J Radiat Oncol Biol Phys, 82(1), 468-474, 2012
DOI
|
11 |
International Commission on Radiation Units and Measurements. ICRU report 62. Prescribing, recording and reporting photon beam therapy. Supplement to ICRU report 50 1999 Bethesda, MD: ICRU
|
12 |
Keal P, Vedam SV, George R et al.: The clinical implementation of respiratory-gated intensitymodulated radiotherapy, Med Dosim, 31(2), 152-162, 2006
DOI
|
13 |
Wallis JW, Lerner TR, Lerner CA: Three-dimensional display in nuclear medicine, Med Imag IEEE Trans, 8(2), 297-330, 1989
DOI
|
14 |
Wolf MC, Stahl M, Krause BJ et al.: Curative treatment of esophageal carcinoma: Current options and future developments, Radiat Oncol, 6(1), 55, 2011
DOI
|
15 |
Teoh AY, Chiu PW, Yeung WK et al.: Long-term survival outcomes after definitive chemoradiation versus surgery in patients with resectable squamous carcinoma of the esophagus: Results from a randomized controlled trial, Ann Oncol, 24(1), 165-171, 2012
DOI
|
16 |
Cunningham D, Starling N, Ashley S: Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 362(9), 858-859, 2010
DOI
|
17 |
Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD: Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemo-radiotherapy, Int J Radiat Oncol Biol Phys, 73(3), 818-823, 2009
DOI
|
18 |
Minsky BD, Pajak TF, Ginsberg RJ et al.: INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy, J Clin Oncol, 20(5), 1167-1174, 2002
DOI
|
19 |
Zhang Z, Liao Z, Jin J et al.: Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy, Int J Radiat Oncol Biol Phys, 61(3), 656-664, 2005
DOI
|
20 |
Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R: Systematic overview of preoperative (neoadjuvant) chemo-radiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response, Radiother Oncol, 78(3), 236-244, 2005
DOI
|
21 |
Gwynne S, Falk S, Gollins S et al.: Oesophageal chemo-radiotherapy in the UK: current practice and future directions, Clin Oncol (R Coll Radiol), 25(6), 368-377, 2013
DOI
|
22 |
Martel MK, Sahijdak WM, Ten Haken RK, Kessler ML, Turrisi AT: Fraction size and dose parameters related to the incidence of pericardial effusions, Int J Radiat Oncol Biol Phys, 40(1), 155-161, 1998
DOI
|
23 |
Hatakenaka M, Yonezawa M, Honda H: Acute cardiac impairment associated with concurrent chemo- radiotherapy for esophageal cancer: Magnetic resonance evaluation, Int J Radiat Oncol Biol Phys, 83(1), e67-e73, 2012
DOI
|
24 |
Bedenne L, Michel P, Bouche O et al.: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102, J Clin Oncol, 25(10), 1160-1168, 2007
DOI
|
25 |
Higuchi K, Koisumi W, Hayakawa K: A phase I trial of definitive chemo-radiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501), Radiother Oncol, 87(3), 398-404, 2008
DOI
|
26 |
Ishida K, Ando N, Yamamoto S, Ide H, Shioda M: Phase II study of cisplatin and 5 fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516), Jpn J Clin Oncol, 34(10), 615-619, 2004
DOI
|
27 |
Ilson DH, Ajani J, Bhalla K et al.: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus, J Clin Oncol, 16(5), 1826-1834, 1998
DOI
|
28 |
Dunne AL, Mothersill C, Robson T, Wilson GD, Hirst DG: Radiosensitization of colon cancer cell lines by docetaxel: Mechanisms of action, Oncol Res, 14(9), 447-454, 2004
DOI
|
29 |
Donahue JM, Nichols FC, S chomas DA et al.: Complete pathologic response after neoadjuvant chemo-radiotherapy for esophageal cancer is associated with enhanced survival, Ann Thorac Surg, 87(2), 398-398, 2009
|
30 |
Siegel R, Naishadham D, Jemal A: Cancer statistics 2012, Cancer J Clin, 62(1), 10-29, 2012
DOI
|
31 |
Orringer MB, Marshall B, Iannettoni MD: Transhiatal esophagectomy: clinical experience and refinements, Ann Surg, 230(3), 392-400, 1999
DOI
|
32 |
Chang AC, Ji H, Birkmeyer NJ, Orringer MB, Birkmeyer JD: Outcomes after transhiatal and transthoracic esophagectomy for cancer, Ann Thorac Surg, 85(2), 424-429, 2008
DOI
|
33 |
Prins MJ, Ruurda JP, van Diest PJ, van Hillegersberg R, Ten Kate FJ: The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study, Ann Oncol, 24(5), 1290-1297, 2013
DOI
|
34 |
Suzuki A, Xiao L, Hayashi Y et al.: Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemo-radiotherapy, Cancer, 117(21), 4823-4833, 2011
DOI
|
35 |
Gillies RS, Middleston MR, Han C et al.: Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma, Br J Surg, 99(2), 239-245, 2012
DOI
|